Axovant Sciences (AXON): Competitive Impact Should Be Minimal - Jefferies

September 23, 2016 7:39 AM EDT
Get Alerts AXON Hot Sheet
Price: $13.84 +0.51%

Rating Summary:
    8 Buy, 0 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 26 | Down: 28 | New: 38
Trade AXON Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Axovant Sciences (NYSE: AXON) after Lundbeck announced that the PIII trial testing idalopirdine failed to meet its primary endpoint of reduction in ADAS-COG at week 24 when combined with donepezil. The analyst believes there are multiple key differences to AXON's intepirdine program and therefore does not expect it to be predictive of the MINDSET Phase III trial outcome. The analyst continues to be positive on AXON’s intepirdine in Alzheimer's.

No change to the price target of $31.

For an analyst ratings summary and ratings history on Axovant Sciences click here. For more ratings news on Axovant Sciences click here.

Shares of Axovant Sciences closed at $15.14 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment